American Scientific Resources shall.

, today verified that it provides signed a letter of intent to acquire the intellectual home to the Disintegrator house needle destruction device . American Scientific Resources shall, upon closing, hold the privileges to the patent, a property of Safeguard Medical Technologies. The Company is seeking the privileges to the patent within ASR’s intend to introduce the merchandise commercially in the fall of 2009. Specific conditions have not been disclosed pending effective negotiation of the contract. Related StoriesNew Cleveland Clinic research shows bariatric surgery is safe choice for managing type 2 diabetes in over weight or mildly obese patientsStudy finds high prevalence of dehydration in older people living in UK care homesWeight-loss surgery may be safe for managing type 2 diabetes in individuals with mild obesityCurrently the just FDA authorized NDD for house make use of, the Disintegrator enables patients who give themselves injections, including those suffering from multiple diabetes or sclerosis, to and safely get rid of needles in the home properly.Frederick Rivara, a UW professor pediatrics, and Dr. Gregory Jurkovich, a UW professor of surgery; in addition to by Dr. Peter Roy-Byrne, a UW professor of psychiatry and behavioral sciences; Joan Russo, Ph.D., a UW analysis associate professor of psychiatry and behavioral sciences; and Dr. Wayne Katon, a UW professor of psychiatry and behavioral sciences. RoseAnne Droesch, M.S.W., of the Harborview Damage Prevention & Research Center formerly, served mainly because trauma support expert; Amy Wagner, Ph.D., a UW assistant professor of psychiatry and behavioral sciences, oversaw the development and implementation of the cognitive behavioral therapy component; and Chris Dunn, Ph.D., a UW assistant professor of psychiatry and behavioral sciences, oversaw the execution of the motivational interviewing component.

Boehringer Ingelheim initiates enrollment in BI 201335 Stage 3 clinical trial for chronic HCV Boehringer Ingelheim Pharmaceuticals, Inc.